SCHEMBL12419232

SCHEMBL12419232

OB(O)c1ccc2nc(Oc3ccccc3O)ccc2c1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CA1 P00915 3/20 0.44
CA2 P00918 3/20 0.44
ENPP2 Q13822 2/20 0.34
GAA P10253 3/20 0.33
JAK2 O60674 1/20 0.33
LMNA P02545 1/20 0.33
MAPT P10636 1/20 0.33
POLB P06746 1/20 0.33
KMT2A Q03164 1/20 0.33
RAB9A P51151 1/20 0.32
HSD17B10 Q99714 1/20 0.32
TP53 P04637 1/20 0.32
TSHR P16473 1/20 0.32
TTR P02766 2/20 0.31
KDM4E B2RXH2 1/20 0.31
ALDH1A1 P00352 1/20 0.31
HPGD P15428 1/20 0.31
STAT3 P40763 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12419231 0.85 CA1 (0.42) CA1CA2ENPP2KMT2ARAB9A
SCHEMBL12419227 0.85 ALDH1A1 (0.47) CA1CA2ENPP2KMT2ATTR
SCHEMBL12419220 0.81 CA1 (0.51) CA1CA2ENPP2LMNAMAPT
SCHEMBL10767713 0.79 ECE2 (0.42) CA1CA2GAAJAK2LMNA
SCHEMBL12419254 0.78 SCN7A (0.44) CA1CA2ENPP2KDM4E
SCHEMBL12419233 0.74 CA1 (0.44) CA1CA2ENPP2POLBTTR
SCHEMBL12419239 0.73 HTT (0.42) CA1CA2ENPP2LMNAMAPT
SCHEMBL12419222 0.73 ENPP2 (0.53) CA1CA2ENPP2KMT2AHSD17B10
SCHEMBL12419230 0.73 MAP4K4 (0.49) CA1CA2ENPP2LMNATTR
SCHEMBL12419251 0.73 MAP4K4 (0.47) CA1CA2LMNAMAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150368278-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. (US) 2015-12-24 US disclosed
US-20150368278-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. (US) 2015-12-24 US disclosed
US-8957049-B2 Inhibitors of fatty acid amide hydrolase INFINITY PHARMACEUTICALS, INC. (US) 2015-02-17 US disclosed
US-8957049-B2 Inhibitors of fatty acid amide hydrolase INFINITY PHARMACEUTICALS, INC. (US) 2015-02-17 US disclosed
US-20110172186-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. 2011-07-14 US disclosed
US-20110172186-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. 2011-07-14 US disclosed
WO-2009126691-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC (US) 2009-10-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172186-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE FAAH, FAAH2, ASAH1 CA1 822/4885CA2 1487/4885ENPP2 68/4885
US-20150368278-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE FAAH, FAAH2, ASAH1 CA1 822/4885CA2 1487/4885ENPP2 68/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.